Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin/docetaxel for non‐small cell lung cancer: Analysis of dose‐volume parameters

BACKGROUND: Radiation pneumonitis (RP) is a major pulmonary adverse event of chest radiotherapy. The PACIFIC trial that identified durvalumab as an effective subsequent‐line therapy after concurrent chemoradiotherapy (CCRT) found that patients with grade 2 or higher RP may have to be excluded from t...

Descripción completa

Detalles Bibliográficos
Autores principales: Katsui, Kuniaki, Ogata, Takeshi, Watanabe, Kenta, Katayama, Norihisa, Kuroda, Masahiro, Kiura, Katsuyuki, Hiraki, Takao, Maeda, Yoshinobu, Toyooka, Shinichi, Kanazawa, Susumu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333825/
https://www.ncbi.nlm.nih.gov/pubmed/32364685
http://dx.doi.org/10.1002/cam4.3093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333825/
https://www.ncbi.nlm.nih.gov/pubmed/32364685
http://dx.doi.org/10.1002/cam4.3093

Ejemplares similares